Core Viewpoint - The article emphasizes the impressive performance of Ping An Fund's equity investment capabilities, highlighting their ability to capture structural market opportunities and achieve significant returns through a well-integrated research and investment mechanism known as the "Four Truths" [2][9]. Group 1: Performance Highlights - In the past year, 60% of Ping An Fund's actively managed equity funds (32 out of 53) achieved returns exceeding 50%, while 80% (43 funds) surpassed 30% [2]. - Notable fund managers like Zhou Sicong and Zhang Yinxian have successfully capitalized on themes such as innovative pharmaceuticals and robotics, with their funds achieving returns of 109.98%, 108.82%, and 146.26% respectively [5][6]. - The fund's performance in the AI sector also stands out, with returns of 88.61% and 66.14% from key products managed by fund managers Zhai Sen and Lin Qingyuan [6]. Group 2: Investment Strategy - Ping An Fund employs a dual strategy of "thematic tracks and full-market stock selection," allowing for diversified investment across various sectors [3]. - The fund managers focus on high-growth areas such as innovative pharmaceuticals, robotics, and AI, which have shown significant market potential [4][5][6]. - The "Four Truths" mechanism supports this strategy by ensuring that research outcomes are effectively translated into practical investment decisions [9]. Group 3: Research and Development Mechanism - The "Four Truths" mechanism consists of "True Mechanism, True Team, True Talent, and True Words," which collectively enhance the fund's investment performance [9][12]. - The internal culture promotes transparency and meritocracy, allowing fund managers and researchers to collaborate closely and share insights [10][11]. - The fund emphasizes continuous talent development through a dual approach of internal training and external recruitment, fostering a diverse and skilled investment team [13]. Group 4: Future Outlook - Looking ahead, Ping An Fund remains committed to long-term investment principles, prioritizing the interests of investors and focusing on in-depth research to uncover quality investment opportunities [14].

Group 1 - The core viewpoint of the article highlights that funds focused on innovative pharmaceuticals have seen significant gains, with some funds increasing over 61% in the first half of the year [1] - The top-performing funds include several that are primarily invested in innovative drugs, with the highest return being 86.48% for the fund "汇添富音港优势精选A" [1] - Other notable funds in the top 16 also show strong performance, with returns ranging from 61.77% to 83.15% [1] Group 2 - The article suggests that innovative drugs can be pursued when the market declines, indicating a potential buying opportunity [2] - The "广发成长领航一年持有A" fund has a significant portion of its holdings in new consumer concepts, with major investments in companies like 泡泡玛特 and 老铺黄金 [3] - The fund manager 吴远怡 has demonstrated strong performance across various products, with most showing commendable returns [4] Group 3 - The historical performance of the "广发科技创新" fund shows a maximum drawdown of -53%, indicating high volatility [5] - Overall, the funds discussed are characterized by high volatility and significant drawdowns, making them more suitable for investors willing to buy during market dips [7] - The article emphasizes that these funds may not be suitable for low-risk investors due to their performance characteristics [7]

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with pharmaceutical and biotechnology-themed funds dominating performance rankings [1] - Over 120 funds were liquidated during this period, indicating significant market shifts [1] Performance Summary Top Performing Funds - The top ten stock funds saw significant returns, with the leading fund, Huaan Pharmaceutical Bio A, achieving a return of 66.44% [2] - Other notable performers included Jiashi Huron Selected A (60.26%) and Ping An Pharmaceutical Selected A (58.80%) [2] - The average return of the top ten funds was driven primarily by smaller, actively managed funds, highlighting their flexibility in capturing rapid market movements [5] Underperforming Funds - The worst-performing funds were led by Jianxin China Manufacturing 2025 A, which recorded a decline of 14.68% [4] - Other funds in the bottom tier included Huaxia Advantage Selected and Great Wall Quantitative Selected A, both with declines exceeding 12% [4] - The coal and photovoltaic sectors faced significant downward pressure, with several funds in these categories showing substantial losses [4] Sector Analysis Pharmaceutical and Biotechnology - The pharmaceutical and biotechnology sectors have seen a resurgence after a prolonged adjustment period, driven by improved valuations and supportive policies [5] - The global and domestic biotech investment climate is recovering, contributing to the strong performance of related funds [5] Coal and Photovoltaic Industries - The coal industry is experiencing a shift in supply-demand dynamics, leading to downward pressure on valuations due to economic restructuring and accelerated energy transitions [5] - The photovoltaic sector is facing intensified competition and concerns over overcapacity, impacting short-term profitability and stock performance [5] Market Outlook - The A-share market is expected to show a trend of gradual upward movement in the second half of 2025, supported by increased participation from public funds and favorable policies [6] - However, significant differentiation among sectors may lead to rebalancing pressures, particularly in pharmaceuticals and biotechnology [6] - Investors are advised to analyze macroeconomic trends and industry policies to identify opportunities amidst market volatility [6]